- INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases.
- INMB’s share price just dropped at an all-time low due to a US-related clinical hold for XPro.
- Trials are still ongoing in Australia, and I expect the hold on the US trials to be lifted.
- XPro's potential is enormous as both science and data indicate best-in-class treatment in neurodegenerative diseases.
- With trials being short and small, an investor who is long here should not worry.
For further details see:
INmune Bio: Possibly The Once In A Lifetime Dip